Macular Edema

The AMA has assigned a Category 1 CPT code for Xipere, according to a press release from Bausch + Lomb.

The FDA approved Vabysmo for the treatment of macular edema following retinal vein occlusion, according to a press release from Genentech.

In the phase 3 BALATON and COMINO studies, Vabysmo demonstrated vision maintenance and anatomic improvements up to week 72 in macular edema secondary to retinal vein occlusion, or RVO, according to a Genentech press release.

Consensus statements provide useful guidance on current clinical practice patterns and disease pathophysiology in an ever-evolving landscape of patient care.

The FDA has accepted a supplemental biologics license application from Genentech for Vabysmo for the treatment of macular edema following retinal vein occlusion, according to a company press release.

Vabysmo met the primary endpoint of noninferior visual acuity gains compared with aflibercept treatment at 24 weeks in patients with retinal vein occlusion in the phase 3 BALATON and COMINO studies, according to a Genentech press release.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Sam E. Mansour, MD, discusses positive results from the PALADIN study investigating the Iluvien implant from Alimera for the treatment of diabetic macular edema.

CHICAGO — Patients with diabetic macular edema experienced improved macular thickness during the COVID-19 pandemic, according to a study presented at the American Academy of Ophthalmology meeting.

Cimerli, a biosimilar interchangeable with Lucentis, will launch in the United States on Oct. 3, according to a press release from Coherus BioSciences.